With the guidance and expertise of medical providers, both medications improve glycemic control, reduce body weight, and enhance cardiovascular health, lowering the risk of heart attacks and strokes
For the first time, a pharmacological obesity treatment, semaglutide, has been shown to reduce major adverse cardiovascular events in people with obesity and established cardiovascular disease and there are ongoing cardiovascular outcome trials with other incretin therapies
Dehydration is the most common reversible cause, requiring loss of just 2% of body weight in fluids to trigger symptoms like dizziness and rapid pulse
GLP-1R agonists have reducing neuroinflammation and oxidative stress, neurotrophic effects, decreasing A deposition and tau hyperphosphorylation in AD models, which may be a potential drug for the treatment of AD